Amitriptyline stands as one of the foundational pharmacotherapies in the history of clinical psychopharmacology, maintaining widespread therapeutic utility across psychiatric and neurological domains for over six decades. Initially synthesized as a psychotropic dibenzocycloheptene derivative, this first-generation tricyclic antidepressant (TCA) exhibits a multifaceted pharmacodynamic profile that extends far beyond mood stabilization. Through its potent modulation of monoaminergic neurotransmission, voltage-gated ion channels, and central nociceptive pathways, amitriptyline continues to serve as an indispensable clinical tool in managing treatment-resistant depression, chronic neuropathic pain syndromes, fibromyalgia, and migraine prophylaxis.
Amitriptyline
1. Concise Definition
Amitriptyline is a dibenzocycloheptadiene-derived tricyclic antidepressant that functions predominantly as a non-selective inhibitor of serotonin (5-HT) and norepinephrine (NE) reuptake transporters. In addition to reuptake inhibition, it exerts antagonistic actions across multiple post-synaptic receptors, including histaminergic (H1), muscarinic cholinergic (M1–M5), and alpha-1 adrenergic receptors, alongside direct blockade of voltage-gated sodium and potassium channels.
Clinically, amitriptyline is classified both as an antidepressant and as an analgesic adjuvant. Although newer agents such as selective serotonin reuptake inhibitors (selective serotonin reuptake inhibitors) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have superseded its routine first-line application in major depressive disorder due to superior tolerability and safety indices, amitriptyline remains a gold-standard intervention for various intractable neurological pain syndromes, sleep fragmentation, and functional gastrointestinal disorders.
At the biochemical level, amitriptyline acts as a prodrug and active parent compound simultaneously; hepatic biotransformation yields its active secondary amine metabolite, nortriptyline, which alters the balance of monoaminergic tone toward preferential noradrenergic signaling. Consequently, its overall physiological impact reflects a complex interplay between parent compound activity, active metabolite generation, and extensive receptor antagonism.
2. Etymology & Linguistic Origin
The chemical nomenclature of amitriptyline derives directly from its constituent structural and functional moieties. The prefix ami- stems from the presence of an aliphatic amine functional group (specifically a dimethylaminopropylidene side chain), while -tript- reflects its structural tricyclic nucleus—a fused three-ring core composed of a central cycloheptadiene or cycloheptene ring flanked by two benzene rings (dibenzo- moiety). The terminal suffix -yline is a standardized chemical suffix denoting unsaturated hydrocarbon chains or specific alkaloid/synthetic derivatives within organic pharmacology.
Introduced to pharmacology under its International Nonproprietary Name (INN) “amitriptyline,” the molecule was originally synthesized by Merck Sharp & Dohme in the late 1950s. The parent chemical identifier, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine, emphasizes the exocyclic double bond bridging the central seven-membered cycloheptene ring to the dimethylaminopropylidene tail.
3. Pronunciation & Grammatical Form
Pronunciation: /ˌæm.ɪˈtrɪp.tɪ.liːn/ (am-ih-TRIP-tih-leen).
Part of Speech: Noun (uncountable when referring to the chemical substance or active pharmaceutical ingredient; countable when referencing specific preparations or formulations).
Grammatical Variants: Amitriptylinic (adjectival form, uncommon); amitriptyline hydrochloride (chemical salt formulation, noun phrase).
Usage Conventions: In standard biomedical writing, amitriptyline is styled in lowercase when referring to the generic drug substance, following the American Medical Association (AMA) and World Health Organization (WHO) conventions. Proprietary brand names—such as Elavil, Endep, or Tryptanol—are capitalized. The compound is typically formulated as amitriptyline hydrochloride for oral tablet and solution administration.
4. Detailed Conceptual Explanation
Amitriptyline occupies a uniquely intricate position within neuropharmacology due to its broad spectrum of molecular targets, a property historically referred to as “pharmacological promiscuity” or “dirty drug pharmacodynamics.” Rather than selectively targeting a single macromolecular transporter, amitriptyline engages a broad array of transmembrane proteins, ion channels, and intracellular signaling cascades. This pleiotropic mechanism underlies both its high therapeutic efficacy in refractory clinical conditions and its extensive side effect burden.
The foundational mechanism of amitriptyline involves competitive antagonism at the human serotonin transporter (serotonin transporter, SERT) and norepinephrine transporter (NET). By physically obstructing the substrate-binding pockets of these presynaptic reuptake complexes, amitriptyline prevents the clearance of 5-HT and NE from the synaptic cleft. This leads to prolonged monoaminergic residency time, increased receptor occupancy, and progressive downstream neuroplastic adaptations within the prefrontal cortex, hippocampus, and descending pain-modulating pathways of the spinal cord.
Beyond reuptake inhibition, amitriptyline exhibits notable affinity for peripheral and central sodium channels. It binds to voltage-gated sodium channels (specifically Nav1.7, Nav1.8, and cardiac Nav1.5 isoforms) in their inactivated state, attenuating high-frequency neuronal firing and ectopic action potential generation. This membrane-stabilizing property is central to its utility in halting neuropathic pain signal transmission, though it concurrently accounts for its pronounced cardiotoxicity in overdose scenarios.
The drug also displays high affinity for heterotrimeric G-protein-coupled receptors. It functions as a competitive antagonist at post-synaptic histamine H1 receptors, muscarinic acetylcholine receptors (subtypes M1 through M5), and alpha-1 adrenergic receptors. Antagonism at histamine H1 receptors confers marked sedative and orexigenic properties, rendering low-dose amitriptyline particularly effective for comorbid insomnia and chronic pain. Conversely, its anticholinergic actions induce xerostomia, blurred vision, urinary retention, and cognitive slowing, necessitating cautious clinical monitoring.
5. Historical Development
The genesis of amitriptyline arose from the mid-twentieth-century revolution in psychopharmacology, catalyzed by the serendipitous discovery of chlorpromazine and imipramine. Following Roland Kuhn’s 1957 identification of imipramine’s antidepressant efficacy in Switzerland, medicinal chemists sought to modify the central dibenzazepine core to synthesize structurally analogous compounds with enhanced psychotropic properties and reduced toxicity.
In 1958, researchers at Merck Sharp & Dohme synthesized amitriptyline by replacing the central ring’s nitrogen atom with a carbon atom linked via an exocyclic double bond, converting the iminodibenzyl nucleus into a dibenzocycloheptadiene structure. Led by chemist Lyle M. Rice and colleagues, this modification produced an agent with higher lipophilicity and pronounced central sedating qualities.
Clinical trials conducted in the late 1950s and early 1960s confirmed that amitriptyline demonstrated marked therapeutic efficacy in severe endogenous depression, often outperforming imipramine in agitated or anxious depressed cohorts due to its prominent anxiolytic and sedative properties. The United States Food and Drug Administration (FDA) approved amitriptyline hydrochloride under the trade name Elavil in April 1961.
During the 1970s and 1980s, amitriptyline became the most widely prescribed antidepressant worldwide. However, researchers gradually recognized its distinct pharmacological utility in non-psychiatric disorders. Seminal investigations by pain researchers and neurologists demonstrated that sub-antidepressant doses (typically 10 to 50 mg daily) significantly mitigated diabetic peripheral neuropathy, postherpetic neuralgia, tension-type headache, and chronic migraine. While the advent of fluoxetine in 1987 precipitated a transition away from TCAs for mood disorders, amitriptyline found a permanent niche in pain medicine and neurotherapeutics.
6. Theoretical Foundations & Pharmacological Mechanism
The classic monoamine hypothesis of depression posits that affective disorders originate from functional deficits in monoaminergic neurotransmission, specifically serotonin and norepinephrine, within limbic and cortical microcircuits. Amitriptyline directly supports this paradigm by elevating synaptic monoamine concentrations within minutes of administration. However, because its clinical antidepressant benefits require two to four weeks of sustained dosing, modern neurobiology attributes its therapeutic action to downstream gene expression changes, neurogenesis, and synaptogenesis mediated by brain-derived neurotrophic factor (brain-derived neurotrophic factor, BDNF) and tropomyosin receptor kinase B (TrkB) signaling.
In chronic pain paradigms, amitriptyline’s efficacy is explained through the gate control theory of pain and the augmentation of descending inhibitory pathways. Under normal physiological conditions, descending noradrenergic and serotonergic fibers originating in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) project to the dorsal horn of the spinal cord, where they inhibit presynaptic primary afferent nociceptors and postsynaptic second-order projection neurons via alpha-2 adrenergic and 5-HT1A/5-HT1B/5-HT3 receptors. In persistent neuropathic states, this endogenous inhibitory system fails. Amitriptyline restores descending monoaminergic inhibition, effectively dampening hyperalgesia and allodynia.
Recent molecular research has uncovered additional neuroprotective and anti-inflammatory mechanisms. Amitriptyline functions as an agonist at the TrkA and TrkB neurotrophin receptors independently of neurotrophins, promoting neuronal survival. Furthermore, it downregulates microglial activation and attenuates proinflammatory cytokine production (such as tumor necrosis factor-alpha, IL-1beta, and IL-6) within neurovascular niches, countering the central neuroinflammation implicated in chronic pain consolidation and neurodegenerative pathology.
7. Key Components, Formulations & Receptor Targets
The pharmacodynamics and physicochemical attributes of amitriptyline encompass several distinct structural components, receptor affinities, and pharmaceutical formulations:
- Molecular Structure: Amitriptyline consists of a tricyclic nucleus (dibenzo[a,d]cycloheptene) bridged to an aliphatic dimethylaminopropylidene side chain, with the molecular formula C20H23N and a molecular weight of 277.40 g/mol.
- Serotonin Transporter (SERT) Inhibition: Displays high nanomolar affinity for human SERT (equilibrium dissociation constant, Ki ≈ 2.8–4.3 nM), potently blocking 5-HT reuptake.
- Norepinephrine Transporter (NET) Inhibition: Demonstrates moderate-to-high affinity for human NET (Ki ≈ 19–35 nM), dampening presynaptic NE clearance.
- Histamine H1 Receptor Antagonism: Exhibits potent inverse agonism/antagonism at H1 receptors (Ki ≈ 1.0–1.1 nM), inducing profound sedation, somnolence, and weight gain.
- Muscarinic Cholinergic Receptor Antagonism: Exerts unselective competitive blockade across M1 through M5 muscarinic receptors (Ki ≈ 10–25 nM), causing peripheral parasympatholytic effects such as dry mouth, cycloplegia, constipation, tachycardia, and cognitive disruption.
- Alpha-1 Adrenergic Antagonism: Moderately blocks post-synaptic alpha-1A and alpha-1B receptors (Ki ≈ 24–27 nM), contributing to peripheral vasodilation and orthostatic hypotension.
- Ion Channel Modulation: State-dependently blocks voltage-gated sodium channels (Nav1.5, Nav1.7, Nav1.8) and inwardly rectifying potassium channels (hERG/IKr), imparting local anesthetic actions while predisposing to electrocardiographic QTc and QRS prolongation.
- Active Metabolite (Nortriptyline): Undergoes N-demethylation to nortriptyline, which displays markedly reduced serotonergic and anticholinergic affinity but elevated noradrenergic selectivity (NET Ki ≈ 1.8–4.4 nM).
- Pharmaceutical Formulations: Primarily supplied as oral tablets (10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg), oral oral solutions, and historically as an intramuscular or intravenous injectable solution in select international jurisdictions.
8. Clinical Indications & Illustrative Cases
The clinical application of amitriptyline spans both psychiatric indications and broad off-label neurological applications supported by substantial clinical trial evidence.
Major Depressive Disorder (MDD)
Amitriptyline is FDA-approved for the treatment of major depressive disorder. Although largely superseded by SSRIs, it remains a valuable option for treatment-resistant depression, severe melancholic depression, and inpatient psychiatric populations where pronounced psychomotor agitation or severe sleep disturbance coexists with affective dysfunction. Therapeutic antidepressant doses typically range from 75 mg to 150 mg daily in divided or single nocturnal doses, titrating up to 300 mg daily in monitored hospital settings.
Neuropathic Pain and Fibromyalgia
Amitriptyline represents a first-line pharmacotherapeutic option recommended by the International Association for the Study of Pain (IASP) and the European Federation of Neurological Societies (EFNS) for neuropathic pain, including diabetic sensorimotor polyneuropathy, postherpetic neuralgia, and central post-stroke pain. In fibromyalgia, randomized controlled trials demonstrate that low-dose amitriptyline (10–50 mg daily) significantly reduces pain scores, stiffness, and fatigue while improving restorative slow-wave sleep architecture.
Migraine and Chronic Tension-Type Headache Prophylaxis
The American Headache Society and the American Academy of Neurology endorse amitriptyline as a first-line agent for migraine prevention. At doses of 10 to 75 mg taken at bedtime, amitriptyline reduces headache frequency, severity, and duration through central antinociception and cortical spreading depression attenuation.
Illustrative Case Vignette 1: Diabetic Neuropathy
A 58-year-old male with a 12-year history of type 2 diabetes presents with progressive burning pain, allodynia, and paresthesias in both feet, causing severe sleep disruption. Previous monotherapy with duloxetine was discontinued due to persistent nausea. The clinician initiates amitriptyline at 10 mg taken orally one hour before bedtime. Over four weeks, the dose is titrated to 25 mg nightly. The patient reports a 60% reduction in nocturnal burning sensations and normalization of sleep patterns, with mild, manageable morning xerostomia.
Illustrative Case Vignette 2: Treatment-Resistant Melancholia
A 46-year-old female with severe recurrent major depressive disorder exhibits profound anhedonia, psychomotor agitation, early-morning awakening, and anorexia with weight loss. She previously failed sequential trials of escitalopram, venlafaxine, and bupropion. Following baseline electrocardiography confirming a normal QTc interval, the patient is commenced on amitriptyline at 50 mg nightly, titrated over three weeks to 150 mg nightly. By week six, she demonstrates significant clinical improvement with remission of depressive symptoms, sustained sleep maintenance, and partial weight restoration.
9. Pharmacokinetics, Dosing & Therapeutic Drug Monitoring
Amitriptyline displays well-characterized, albeit variable, pharmacokinetic properties across diverse patient populations. Following oral administration, the drug is rapidly and completely absorbed from the gastrointestinal tract. However, it undergoes extensive first-pass hepatic metabolism, resulting in a systemic bioavailability ranging between 30% and 60%.
Peak plasma concentrations (Cmax) are typically reached within 2 to 4 hours post-ingestion. Amitriptyline is highly lipophilic and widely distributed throughout bodily tissues, exhibiting an apparent volume of distribution (Vd) of 12 to 18 L/kg. Plasma protein binding is extensive, with approximately 95% of circulating drug bound to plasma albumin and alpha-1-acid glycoprotein.
Hepatic clearance is mediated predominantly by the cytochrome P450 (cytochrome P450) enzyme superfamily. Amitriptyline undergoes N-demethylation primarily via CYP2C19, with secondary contributions from CYP3A4 and CYP1A2, to form its primary active metabolite, nortriptyline. Both amitriptyline and nortriptyline undergo subsequent aromatic hydroxylation mediated primarily by CYP2D6 to form 10-hydroxy metabolites, which are subsequently conjugated with glucuronic acid and excreted via the kidneys. The mean elimination half-life of amitriptyline ranges from 16 to 25 hours, while that of active nortriptyline ranges from 18 to 44 hours, supporting once-daily bedtime dosing regimens.
Because CYP2D6 and CYP2C19 exhibit substantial genetic polymorphism, therapeutic drug monitoring (TDM) provides valuable clinical utility. Patients classified as CYP2D6 or CYP2C19 poor metabolizers experience marked drug accumulation and elevated toxicity risks at standard doses, whereas ultra-rapid metabolizers may fail to achieve therapeutic plasma thresholds. In major depressive disorder, the established combined therapeutic reference window for amitriptyline plus nortriptyline is 100 to 250 ng/mL. Concentrations exceeding 300 ng/mL substantially increase the risk of severe cardiotoxicity and central nervous system adverse events without providing additional therapeutic benefit.
10. Adverse Effects, Toxicity & Safety Profile
The clinical utility of amitriptyline is constrained by a well-documented spectrum of side effects and high lethality in acute overdose situations.
Anticholinergic and Autonomic Adverse Effects
Muscarinic receptor blockade frequently leads to peripheral anticholinergic effects, including xerostomia (dry mouth), constipation, blurred vision due to cycloplegia, urinary retention, and anhidrosis. Centrally, anticholinergic action can precipitate delirium, restlessness, and memory impairment, particularly in geriatric populations or individuals with underlying neurocognitive impairment. Alpha-1 adrenergic antagonism promotes peripheral vasodilation and reflex orthostatic hypotension, elevating fall risks.
Central Nervous System Effects
Histaminergic H1 receptor antagonism produces pronounced daytime somnolence, fatigue, and psychomotor slowing. Long-term administration can lead to weight gain secondary to hypothalamic H1 and 5-HT2C receptor antagonism, which stimulates appetite and alters metabolic homeostasis. Amitriptyline also reduces the seizure threshold in a dose-dependent fashion, warranting caution in individuals with epilepsy.
Cardiotoxicity and Overdose Profile
Amitriptyline’s most severe hazard is acute cardiotoxicity. In therapeutic dosing, it may induce mild sinus tachycardia via anticholinergic and noradrenergic mechanisms. In acute overdose (typically at ingestions exceeding 10 mg/kg), the drug inhibits myocardial fast sodium channels (Nav1.5), impairing cardiac conduction. This manifests on electrocardiography as PR interval prolongation, marked widening of the QRS complex (>100 ms predicts seizure risk; >160 ms predicts life-threatening ventricular arrhythmias), right-axis deviation of the terminal 40 ms of the QRS complex, and prolongation of the QTc interval, potentially triggering torsades de pointes or ventricular fibrillation.
Emergency management of tricyclic antidepressant toxicity relies on aggressive supportive care, airway protection, and immediate intravenous administration of sodium bicarbonate. Sodium bicarbonate acts through two distinct physiological mechanisms: alkalinizing serum pH (target 7.45–7.55) to shift amitriptyline into its uncharged, less active state and providing an extracellular sodium load that directly outcompetes the drug for cardiac fast sodium channels, thereby narrowing the QRS complex and restoring hemodynamic stability.
11. Research & Empirical Evidence
Over several decades, robust empirical investigations have established amitriptyline’s comparative efficacy across diverse clinical indications. In a landmark network meta-analysis published in The Lancet by Cipriani et al. (2018), which evaluated 21 antidepressants across 522 double-blind randomized trials comprising 116,477 participants with major depressive disorder, amitriptyline ranked as the most efficacious agent among all evaluated compounds in terms of response rate (odds ratio 2.13 compared to placebo). However, its relative acceptability was lower than that of modern selective agents due to high dropout rates driven by adverse effects.
In pain medicine, systematic reviews published by the Cochrane Collaboration confirm amitriptyline’s clear analgesic efficacy. In a comprehensive Cochrane systematic review by Moore et al. (2015), amitriptyline provided significant pain relief (defined as at least 50% pain reduction) in chronic neuropathic pain conditions, with a calculated number needed to treat (NNT) of approximately 3.6 for achieving moderate or substantial relief. Although methodological limitations characterized many older trials, the consistency of findings across diabetic neuropathy and postherpetic neuralgia remains robust.
In chronic migraine prophylaxis, randomized controlled trials comparing amitriptyline to topiramate and propranolol have demonstrated equivalent efficacy in reducing monthly migraine days. Research by Couch et al. and subsequent multi-center headache consortium trials consistently place low-dose amitriptyline among the most cost-effective and clinically reliable prophylactic regimens available globally.
12. Special Populations & Clinical Considerations
Prescribing amitriptyline demands rigorous personalization, particularly across vulnerable patient demographics:
- Geriatric Patients: Older adults are vulnerable to amitriptyline-induced toxicities. The American Geriatrics Society Beers Criteria categorize amitriptyline as potentially inappropriate for older adults due to high risks of orthostatic hypotension, falls, fractures, urinary retention, and anticholinergic-induced delirium or cognitive decline. If a TCA is required in this demographic, secondary amines like nortriptyline or desipramine are preferred.
- Pregnancy and Lactation: Amitriptyline crosses the human placenta. While registry studies have not shown clear evidence of major congenital malformations, exposure in the third trimester can produce neonatal withdrawal symptoms, including irritability, jitteriness, hypothermia, and respiratory depression. Small quantities are excreted into human breast milk; maternal use requires weighing neonatal risks against maternal psychiatric stability.
- Hepatic Impairment: Because amitriptyline is extensively cleared via hepatic phase I oxidative pathways, severe liver disease or cirrhosis significantly increases drug bioavailability and half-life. Conservative dose titration and frequent monitoring are mandatory.
- Renal Impairment: Dosage adjustments are typically not required for mild to moderate renal insufficiency, as the parent compound is primarily cleared hepatically; however, active glucuronide-conjugated metabolites can accumulate in end-stage renal disease.
- Pediatric Considerations: Amitriptyline is indicated in select jurisdictions for nocturnal enuresis in children aged six years and older. However, caution is required regarding accidental poisoning and the boxed warning regarding antidepressant-associated emergent suicidality in children, adolescents, and young adults up to 24 years of age.
13. Criticisms, Debates & Limitations
A central debate surrounding amitriptyline centers on its risk-benefit calculus in modern medicine. Critics argue that its low therapeutic index and significant mortality in intentional overdose make it unsuitable for unmonitored outpatients with active suicidal ideation. Modern clinical guidelines consistently advise prescribing limited quantities to patients at elevated suicide risk to mitigate the danger of fatal self-poisoning.
Another area of contention involves its wide off-label use for functional disorders such as irritable bowel syndrome (IBS), interstitial cystitis, and chronic insomnia. Proponents argue that sub-antidepressant doses (10–25 mg) are well-tolerated, highly effective, and economically accessible. Opponents caution that even low doses carry risks of daytime cognitive slowing, long-term anticholinergic burden linked to future dementia risks in longitudinal epidemiological studies, and metabolic dysregulation.
Furthermore, the advent of monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) for migraine and modern gabapentinoids for neuropathic pain has provoked discussions regarding whether TCAs should be relegated to later lines of therapy. Nevertheless, amitriptyline remains widely used worldwide due to its low cost, broad availability, and established efficacy in treatment-refractory pain and headache conditions.
14. Related Compounds & Comparative Distinctions
Understanding amitriptyline requires contextualizing it within its structural and functional pharmacological class:
- Nortriptyline: The active N-demethylated metabolite of amitriptyline. Nortriptyline is a secondary amine tricyclic antidepressant that acts as a preferential norepinephrine reuptake inhibitor. It produces substantially less sedation, orthostatic hypotension, and anticholinergic disruption, displaying a distinct therapeutic window (“therapeutic window” curve) between 50 and 150 ng/mL.
- Imipramine: A prototypical dibenzazepine tricyclic antidepressant. Imipramine features a central nitrogen atom in its tricyclic core rather than a carbon atom. It undergoes metabolism into desipramine and possesses a pharmacodynamic profile similar to amitriptyline, though with slightly less prominent sedative and anticholinergic potency.
- Clomipramine: The 3-chloro derivative of imipramine. Clomipramine is the most potent serotonergic reuptake inhibitor among all tricyclics (SERT Ki ≈ 0.14 nM), making it a gold standard for severe obsessive-compulsive disorder (OCD), whereas amitriptyline shows lower SERT selectivity and broader antinociceptive utility.
- Duloxetine: A modern non-tricyclic SNRI. Duloxetine inhibits serotonin and norepinephrine reuptake without binding substantially to muscarinic, histaminergic, or alpha-adrenergic receptors. It shares amitriptyline’s indications for neuropathic pain and fibromyalgia but has an improved cardiac safety profile and lower lethality in overdose.
- Gabapentin / Pregabalin: Voltage-gated calcium channel alpha-2-delta ligands. These agents modulate excitatory neurotransmitter release in neuropathic pain without direct monoaminergic reuptake inhibition, offering an alternative mechanism of action devoid of anticholinergic side effects.
15. Summary & Key Takeaways
Amitriptyline remains a versatile, pharmacologically complex medication that helped shape modern psychopharmacology and neurotherapeutics. As a tricyclic dibenzocycloheptadiene derivative, its actions involve potent reuptake inhibition of serotonin and norepinephrine, functional blockade of sodium channels, and antagonism across histaminergic, muscarinic, and adrenergic receptors. While superseded by newer agents as a first-line treatment for major depression due to its anticholinergic side effects and cardiotoxicity in overdose, it remains a gold-standard option for neuropathic pain, migraine prevention, and fibromyalgia at low doses.
Safe and effective clinical use requires understanding its complex pharmacokinetics, including polymorphic CYP2C19 and CYP2D6 metabolism, its narrow therapeutic index, and its distinctive overdose profile, which requires prompt intervention with intravenous sodium bicarbonate. Six decades after its introduction, amitriptyline continues to serve as an effective, highly accessible option in contemporary clinical medicine.
References
- Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Teo, P., Engel, R. R., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7
- Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., Kamerman, P. R., LeMans, K., Raja, S. N., Rice, A. S., Rowbotham, M., Shen, Z., Siddall, P., Raja, S. N., & Wallace, M. (2015). Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. The Lancet Neurology, 14(2), 162–173. https://doi.org/10.1016/S1474-4422(14)70251-0
- Gillman, P. K. (2007). Tricyclic antidepressant pharmacology and overdose. Current Opinion in Psychiatry, 20(1), 81–89. https://doi.org/10.1097/YCO.0b013e328010c71a
- Hicks, J. K., Sangkuhl, K., Swen, J. J., Ellingrod, V. L., Müller, D. J., Shimoda, K., Bishop, J. R., Kharasch, E. D., Skaar, T. C., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Caudle, K. E., & Stingl, J. C. (2017). Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and tricyclic antidepressants: 2016 update. Clinical Pharmacology & Therapeutics, 102(1), 37–44. https://doi.org/10.1002/cpt.597
- Moore, R. A., Derry, S., Aldington, D., Cole, P., & Wiffen, P. J. (2015). Amitriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews, 2015(7), CD008242. https://doi.org/10.1002/14651858.CD008242.pub3